AI for Breast Cancer Screening & Diagnosis
Breast Cancer
Key Facts
About MeVis BreastCare
MeVis BreastCare is a long-established, Bremen-based player in the digital breast imaging space, transitioning its legacy in medical image processing into modern AI-driven diagnostic support tools. The company operates in the high-growth digital health and AI diagnostics sector, targeting the global breast cancer screening market where there is significant demand for tools that improve radiologist efficiency and diagnostic accuracy. As a private company, its financial details are not publicly disclosed, but its mature market presence and focus on a critical oncology indication position it as a specialized technology provider. Its success hinges on clinical validation, integration into diverse healthcare IT systems, and competition against both large medtech conglomerates and agile AI startups.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |